The natural history of prostate cancer

Urologic Clinics of North America

Volumn 30, Issue 2, 2003, Pages 219-226

  Kessler, Brian ^a   Albertsen, Peter ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; DIETHYLSTILBESTROL; ESTRAMUSTINE; MEDROXYPROGESTERONE ACETATE; PROSTATE SPECIFIC ANTIGEN;

AGING; ANTIGEN DETECTION; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; HEALTH HAZARD; HUMAN; LONG TERM CARE; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0037407154     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(02)00182-9     Document Type: Review

References (29)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA, Cancer J Clin 2003;53:5-26.
2. Scardino PT. Early detection of prostate cancer. Urol Clin N Amer 1989;16(4):635-55.
3. Potosky AL, Miller BA, Albertsen PC, Kramer B. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1993;273:548-52.
4. Barnes RW. Survival with conservative therapy. JAMA 1969;210(2):331-2.
5. Gleason DF, Mellinger G. The Veterans Administration Cooperative Urologic Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 1974;111:58-64.
6. Gleason DF. Histologic grading and clinical staging of carcinoma of the prostate. In: Tannenbaum M, editor. Urologic pathology. Philadelphia: Lea & Febiger; 1977. p. 171-98.
7. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostate cancer. JAMA 1992;267:2191-6.
8. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Krusemo UB, Kraaz W. Natural history of prostate cancer: a population based study of 223 untreated patients. Lancet 1989;1:799-803.
9. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277:467-71.
10. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-8.
11. Aus G, Hugosson J, Norlen L. Long term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995;154:460-5.
12. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349:906-10.
13. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626-31.
14. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996;156:127-32.
15. Greenfield S, Giovanni A, McNeil BJ, Cleary PD. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Med Care 1993;31:141-54.
16. Charleson ME, Pompie P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987;40:373-83.
17. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcomes of diabetes mellitus. Journal of Chronic Diseases 1974;27:387-404.
18. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. A competing risk analysis of men age 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-80.
19. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909-16.
20. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ confined prostate cancer is increased through prostate specific antigen based testing. JAMA 1993;270:948-54.
21. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
22. Gann PH, Hennekens CH, Sampfer MJ. A prospective evaluation of plasma prostate specific antigen for detection of prostatic cancer. JAMA 1992;273:289-94.
23. Koppie TM, Grossfeld GD, Miller D, Yu J, Stier D, Broering JM, et al. Patterns of treatment of patients with prostate cancer initially managed with surveilance: results from the CaPSURE database. J Urol 2000;164:81-8.
24. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer?. JAMA 2000;283(2):2975-8.
25. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: interpreting trends in prostate cancer - part I: evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates. J Natl Cancer Inst 1999;91:1017-24.
26. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate cancer trends 1973-1995, SEER Program. Bethesda (MD): National Cancer Institute; 1999. Publication #NIH 99-4543.
27. Ries LA, Eisner MP, Kosary CL, et al, editors. SEER cancer statistics review, 1973-1998. Bethesda (MD): National Cancer Institute, 2001.
28. Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer - part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999;91:1033-9.
29. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer - part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999;91:1025-32.